[ad_1]
By Ludwig Burger
(Reuters) – GlaxoSmithKline (NYSE) said on Thursday that a laboratory analysis of COVID-19 antibody therapy being developed with US partner Vir had shown that the drug was effective against the new Omicron variant.
In a statement, the British pharmacist said that laboratory tests and a study on hamsters have shown that the sotrovimab antibody cocktail works against bio-engineering viruses to carry various distinctive mutations in the Omicron variant.
Tests are continuing to confirm the results against all Omicron mutations, with an update expected by the end of the year, he added.
In particular, on Thursday the British drug regulator approved sotrovimab, also known as the Xevudy brand, for people with mild to moderate COVID-19 who are at high risk of developing a serious illness.
He recommended the use of Xevudy by the Medicines and Health Products Regulatory Agency (MHRA) as soon as possible and within five days of the onset of symptoms.
Fusion Media or anyone involved with Fusion Media will not be held liable for any loss or damage as a result of relying on the information contained in the data, estimates, charts and buy / sell signals contained in this website. Please be informed that one of the most risky forms of investment possible is the full information on the risks and costs associated with trading in the financial markets.
[ad_2]
Source link
